Franciscan Health recruiting adults for COVID-19 clinical trial
BLAZE-1 study evaluating safety, effectiveness of potential antibody treatment INDIANAPOLIS, Indiana | Franciscan Health Indianapolis has begun recruiting and treating patients in a clinical research study to evaluate the safety and effectiveness of an antibody treatment drug, LY-CoV555, in patients with early mild to moderate COVID-19 illness caused by a coronavirus called SARS-CoV-2. Sponsored by Eli Lilly and Company, the BLAZE-1 Study is looking for adults ages 18 and older who have recently tested positive for COVID-19 and are not hospitalized. Franciscan Health Hammond has also been designated as a research site for the BLAZE-1 study and will soon be recruiting patients as well. “Kicking
